Apogee Therapeutics Inc Stock Price, News & Analysis

Apogee Therapeutics (NASDAQ: APGE) reported positive interim Phase 1 results for APG333, a half-life–extended TSLP antibody, from a first‑in‑human, single‑ascending dose study in 32 healthy volunteers on Nov 10, 2025. Key findings: an optimized PK profile with an approximate 55‑day half‑life, durable suppression of eosinophils and IL‑5 out to 6 months after one dose, and tolerability up to 1,000 mg. Results support potential 3‑ to 6‑month dosing and development of a quarterly co‑formulation with APG777 (APG273).

Apogee Therapeutics (Nasdaq: APGE) announced management will participate in five investor conferences in November–December 2025 with scheduled fireside chats and webcasts.

Conferences and times: Guggenheim Healthcare – Nov 11, 2025 at 1:30 p.m. ET; Stifel Healthcare – Nov 12, 2025 at 11:20 a.m. ET; TD Cowen Immunology & Inflammation Virtual Summit – Nov 13, 2025 at 12:30 p.m. ET; Jefferies London Healthcare – Nov 19, 2025 at 3:00 p.m. GMT / 10:00 a.m. ET; Citi Global Healthcare – Dec 3, 2025 at 9:45 a.m. ET.

A live and archived webcast of the fireside chats will be available on the company’s Investors & News & Events webpage.

Apogee Therapeutics (Nasdaq: APGE) closed an underwritten public offering on Oct. 10, 2025, raising approximately $345 million in gross proceeds.

The offering comprised 8,048,782 shares of common stock (including full exercise of the underwriters’ 1,097,561‑share option) and pre‑funded warrants to purchase up to 365,853 shares at a public offering price of $41.00 per share (pre‑funded warrants priced at $40.99999), with the pre‑funded warrants exercisable immediately at an exercise price of $0.00001 per share. Joint book‑running managers included Jefferies, BofA Securities, Guggenheim Securities and TD Cowen.

Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering to raise approximately $300 million in gross proceeds.

The offering includes 6,951,221 shares of common stock at $41.00 per share and pre-funded warrants to purchase up to 365,853 shares at $40.99999 each (exercise price $0.00001), exercisable immediately. The offering is expected to close on October 10, 2025, subject to customary conditions.

Underwriters have a 30-day option to purchase up to 1,097,561 additional shares. Joint book-runners include Jefferies, BofA Securities, Guggenheim Securities and TD Cowen. An automatically effective shelf registration was filed with the SEC on August 12, 2024.

Apogee Therapeutics (Nasdaq: APGE) announced on October 8, 2025 that it has commenced a proposed underwritten public offering of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company said it will grant underwriters a 30-day option to buy up to an additional 15% overallotment of the shares at the public offering price, subject to market conditions and underwriting terms.

Apogee intends to use net proceeds together with existing cash and marketable securities to fund preclinical studies, clinical trials, manufacturing, commercial readiness for its antibody programs, additional R&D, capital expenditures, working capital and general corporate purposes. The offering will be made by written prospectus and is subject to completion and SEC registration requirements.

Apogee Therapeutics (NASDAQ:APGE) announced that data from its Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025 in Paris. The presentation will highlight the drug's 16-week topline data, which successfully met primary and secondary endpoints.

APG777 stands out as the only biologic being tested for 3- and 6-month dosing intervals in maintenance treatment. The company will also present data on APG990 and their combination strategy with APG279, a coformulation designed to inhibit Type 1, Type 2, and Type 3 inflammation, potentially expanding their patient reach.

The presentations include a late-breaker oral session by Dr. Emma Guttman-Yassky and three poster presentations covering the APEX program, APG990's safety profile, and the combination therapy approach.

Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T.

Investors and interested parties can access both the live and archived versions of the fireside chat through the News & Events page in the Investors section of Apogee Therapeutics' website.

Apogee Therapeutics (NASDAQ:APGE) reported significant progress in its pipeline and Q2 2025 financial results. The company announced positive 16-week data from APEX Phase 2 Part A trial for APG777, their anti-IL-13 antibody for atopic dermatitis, meeting all primary and secondary endpoints. APG777 demonstrated 71.0% EASI reduction vs. 33.8% for placebo, with potential for 3-6 month maintenance dosing versus current bi-weekly standard.

Key developments include first patient dosing in Phase 1b head-to-head trial of APG279 versus DUPIXENT, accelerated APEX Phase 2 Part B readout to mid-2026, and ongoing progress with APG333. The company maintains a strong financial position with $621.2 million in cash, providing runway into Q1 2028, despite increased R&D expenses of $55.7 million and net loss of $66.1 million for Q2 2025.

Apogee Therapeutics (NASDAQ:APGE) announced positive 16-week data from Phase 2 APEX clinical trial of APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial achieved all primary and secondary endpoints, with APG777 demonstrating a 71.0% decrease in EASI from baseline at Week 16 and an EASI-75 response rate of 66.9% (42.5% placebo-adjusted), marking the highest efficacy of any biologic in a global study.

The drug showed rapid onset of itch relief and was well-tolerated with a favorable safety profile. Based on exposure-response relationships observed, APEX Part B is testing higher doses with readout accelerated to mid-2026. The company plans to initiate Phase 3 trials in 2026, while also conducting a head-to-head trial of APG279 versus DUPIXENT with results expected in 2H 2026.